Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Authors: Ben Tran, Mark Voskoboynik, Sang-We Kim et al.

Publication:

Published: Unknown date

Source: Crossref

Back to Search View Original Cite This Article

Abstract

<jats:p><p>Supplementary Figure S4. Molecular response dynamics (ctDNA) across all dose levels (225–2500 mg). Percent change from baseline in mVAF up to week 6.</p></jats:p>

Keywords

psupplementary figure molecular response dynamics

Supplementary Figure S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

Abstract

Keywords

Related Articles

Rearrangement of 2-(γ-aminopropyl)benzoxazoles into 2-(α-pyrrolinylamino)phenols: from serendipitous reaction discovery to anti-mycobacterial opportunities

Supplementary Figure S6 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy

Figure 5 from A Urinary Three-Metabolite Signature Enables Noninvasive Identification of Patients with High-Risk Ovarian Cancer

Figure 2 from A Urinary Three-Metabolite Signature Enables Noninvasive Identification of Patients with High-Risk Ovarian Cancer

Figure S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment